Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study. TACE with or without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results